{{Rsnum
|rsid=993648
|Gene=CERKL
|Chromosome=2
|position=181591267
|Orientation=minus
|GMAF=0.4192
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CERKL
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 3.5 | 44.2 | 52.2
| HCB | 16.8 | 41.6 | 41.6
| JPT | 11.5 | 45.1 | 43.4
| YRI | 57.8 | 36.7 | 5.4
| ASW | 49.1 | 42.1 | 8.8
| CHB | 16.8 | 41.6 | 41.6
| CHD | 12.8 | 54.1 | 33.0
| GIH | 5.0 | 23.8 | 71.3
| LWK | 45.5 | 46.4 | 8.2
| MEX | 15.5 | 51.7 | 32.8
| MKK | 37.2 | 44.9 | 17.9
| TSI | 3.9 | 26.5 | 69.6
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs993648
|PubMedID=18521091
|Condition=Response to iloperidone treatment (QT prolongation)
|Gene=CERKL
|Risk Allele=T
|pValue=3.00E-006
|OR=NA
|95CI=
}}

{{PharmGKB
|RSID=rs993648
|Name_s=
|Gene_s=CERKL
|Feature=
|Evidence=PubMed ID:18521091; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia (Initial Sample Size: 183 individuals; Replication Sample Size: NR; Risk Allele: rs993648-T). This variant is associated with Response to iloperidone treatment (QT prolongation).
|Drugs=iloperidone
|Drug Classes=
|Diseases=Acquired Long QT Syndrome (aLQTS); congenital long QT syndrome; Long QT Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356592
}}

{{PMID|20368905|OA=1
}} New atypical antipsychotics for schizophrenia: iloperidone.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs993648
|overall_frequency_n=51
|overall_frequency_d=128
|overall_frequency=0.398438
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=48
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}